KF
TGTX icon

Krilogy Financial’s TG Therapeutics TGTX Stock Holding History

Krilogy Financial’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-500
Closed -$3K – 620
2018
Q3 		$3K Buy
+500
New +$5.71K ﹤0.01% 695
2018
Q2 		– Sell
-500
Closed -$7K – 576
2018
Q1 		$7K Buy
500
+200
+67% +$2.56K ﹤0.01% 571
2017
Q4 		$2K Hold
300
– – ﹤0.01% 707
2017
Q3 		$4K Hold
300
– – ﹤0.01% 684
2017
Q2 		$3K Buy
+300
New +$3.36K ﹤0.01% 647
2016
Q3 		– Sell
-500
Closed -$3K – 772
2016
Q2 		$3K Hold
500
– – ﹤0.01% 662
2016
Q1 		$4K Hold
500
– – ﹤0.01% 561
2015
Q4 		$6K Buy
500
+200
+67% +$2.53K 0.01% 304
2015
Q3 		$3K Buy
+300
New +$4.47K ﹤0.01% 522

Other funds holding TGTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Krilogy Financial's TGTX Position: Q4 2018 in Review

Krilogy Financial sold out of TG Therapeutics (TGTX) in Q4 2018, closing a stake of 500 shares — an estimated $3K sold.

Krilogy Financial first reported a position in TGTX in Q3 2015 and held it in 9 quarters. The position peaked at $7K in Q1 2018. 115 funds tracked by Wall St. Rank hold TGTX as of Q4 2018.

  • Krilogy Financial reported no remaining TG Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Krilogy Financial sold 500 TG Therapeutics shares in Q4 2018, an estimated $3K.
  • Krilogy Financial first reported a position in TG Therapeutics in Q3 2015 and held it in 9 quarters.
  • Krilogy Financial's TG Therapeutics position peaked at $7K in Q1 2018.
  • 115 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2018.

Based on Krilogy Financial's 13F filing for Q4 2018, filed 14 Feb 2019.